Happy sailing, "Bebig"!

Rusnano announces the withdrawal from the capital of the portfolio company "Bebig" – the only Russian manufacturer of micro sources for low-dose brachytherapy of prostate cancer.

During the year of operation, over 10 thousand micro sources were produced, with the help of which more than 1,200 medical operations were performed in Russia in 2014.

The total amount of project financing from Rusnano amounted to 496 million rubles, and proceeds from the portfolio company (repayment of loans, interest on loans issued, profit from the sale of shares) exceeded 670 million rubles by the time of release. The buyer of Rusnano's share was a Russian strategic investor.

Low–dose brachytherapy is one of the modern high-tech types of radiotherapy used to treat prostate cancer. The method is based on the introduction of micro sources of radiation directly into the tumor, which significantly reduces the side effects characteristic of remote radiation therapy: radiation does not affect the tissues and organs adjacent to the tumor focus.

Vladimir Avetisyan, Deputy Chairman of the Board of Rusnano: "The company has not just created a high-tech production in Russia, but has actually introduced an advanced method of treatment nationwide: with the assistance of Bebig LLC, training seminars were held for medical personnel, including abroad. Thanks to the financial, administrative and consulting support of Rusnano, the annual revenue of Bebig LLC has doubled during the implementation of the project – from 200 million rubles in 2010 to more than 400 million rubles by the end of 2014, in 2015 we expect no less."

Olga Shpichko, Managing Director of Rusnano: "We have managed to localize in Russia one of the most effective technologies for the production of innovative medical products. The plant's robotic line is designed for minimal human intervention: automation ensures the manufacture of the product and the strictest quality control."

Kirill Mayorov, CEO of Bebig LLC: "Today, treatment using our products is carried out in 26 largest medical centers in the territory of the Russian Federation. The high production capacity of the plant will allow us to supply products abroad in the near future, in particular, to clinics in the CIS countries and the Middle East."

Prostate cancer is among the most common oncological diseases. In 2014, 36,493 patients were diagnosed. For patients with stage I and II cancer, brachytherapy is a particularly gentle, alternative method to surgery or external irradiation.

Reference

Brachytherapy is a highly effective method of treating prostate cancer, in 98% of cases completely destroying the malignant disease. The main component of the operation is radioactive radiation implanted around the perimeter of the tumor.

The method of low-dose brachytherapy is based on implantation of micro sources of radioactive radiation based on iodine-125 along the perimeter of the tumor and is a low-traumatic treatment method that does not affect male potency and allows to preserve male health.

The brachytherapy method has been widely used in Europe and America for 30 years. In Russia, low-dose brachytherapy for prostate cancer is included in the list of types of high-tech medical care, funded, among other things, by the state under the program of state guarantees of free medical care to citizens of the Russian Federation and is the most cost-effective, both for patients and for medical institutions.

With early detection of prostate cancer and indications for brachytherapy, citizens of the Russian Federation can use this method of treatment for free, in any medical institution where there are quotas.

Portal "Eternal youth" http://vechnayamolodost.ru

15.10.2015